The Recorder | Live Nation Entertainment’s Board of Directors Hit with Securities Complaint Tied to DOJ Antitrust Suit

Alston & Bird secured a significant victory for Massachusetts-based Checkpoint Therapeutics, a biopharmaceutical company specializing in cancer immunotherapies and treatments, and its CEO in a securities class action in the Southern District of New York. The suit alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act, claiming the company made materially false or misleading statements about the likelihood of Food and Drug Administration approval for a biologics license application. In a detailed ruling issued May 19, the court granted our motion to dismiss the case with prejudice, finding the plaintiff failed to adequately plead any false or misleading statements or the scienter required for securities fraud.

This article outlines the recent Fourth Circuit ruling to curtail plaintiffs' ability to rely on short-seller reports as corrective disclosures for pleading the loss causation element of a federal securities law claim.

This article outlines how many parenting skills we use to help our kids through challenges can also teach us the fundamentals of leading clients through a corporate crisis.

Kim Peretti and Cara Peterman will present a cyber table top exercise at this event hosted by the National Association of Corporate Directors.

Susan Hurd is quoted on the likelihood of more securities class actions.

Susan Hurd is quoted on a potential uptick in securities class actions.

Our Securities Litigation Group examines the Fourth Circuit decision to limit plaintiffs’ use of short seller reports to plead federal securities claims.

This article discusses how the Supreme Court’s Moab ruling has unexpectedly given defendants the ability to have claims based on “pure omissions” dismissed – even beyond Item 303 claims like the one in Moab.

Andy Sumner is quoted on a Delaware bill (SB 21) that would expand the state’s safe harbor procedures for corporations.